Last week, the Food and Drug Administration approved aducanumab to treat Alzheimerâ€™s disease, which is a progressive brain disorder that is the most common cause of dementia.
Aducanumab targets amyloid plaques in the brain that are believed to be an essential component of Alzheimerâ€™s disease. But what does the approval of a new Alzheimer’s drug mean for patients?
On the Mayo Clinic Q&A podcast, Dr. Ronald Petersen, a Mayo Clinic neurologist and director of Mayo Clinicâ€™s Alzheimerâ€™s Disease Research Center, and Dr. David Knopman, a Mayo Clinic neurologist, discuss the challenges ahead to identify the appropriate patients for treatment with aducanumab.
Read the full transcript.
Dr. Petersen has consulted with Biogen on aducanumab, but he was not involved in the design or execution of the clinical trials.
Dr. Knopman is a former member of the FDA’s Peripheral and Central Nervous System Advisory Committee, but he was recused for the aducanumab advisory hearing because he was a site principal investigator for one of Biogen’s aducanumab trials.
Mayo Clinic campuses in Rochester, Minnesota, and Jacksonville, Florida, participated in aducanumab clinical trials.
For the safety of its patients, staff and visitors, Mayo Clinic has strict masking policies in place. Anyone shown without a mask was recorded prior to COVID-19 or recorded in an area not designated for patient care, where social distancing and other safety protocols were followed.